Europe Liquid Biopsy Market to Grow with a CAGR of 11.72% through 2030
Expansion
of liquid biopsy applications beyond oncology and rising investment in
precision diagnostics, is expected to drive the Europe Liquid Biopsy Market
growth in the forecast period, 2026-2030
According to
TechSci Research report, “Europe Liquid Biopsy Market – By Country, Competition, Forecast & Opportunities, 2030F”, the Europe Liquid Biopsy
Market was valued at USD 1.16
Billion in 2024 and is expected to reach USD 2.26 Billion by
2030 with a CAGR of 11.72%.
The Europe Liquid Biopsy Market is poised for significant growth, driven by an
increasing preference for less invasive diagnostic methods and advancements in
molecular biology. Liquid biopsy is emerging as a game-changer for detecting a
range of cancers, offering faster and more precise testing compared to
traditional biopsy methods. This non-invasive procedure is becoming the go-to
choice for early cancer detection, especially as it enables continuous
monitoring of tumor dynamics throughout treatment. As healthcare systems across
Europe strive for more cost-effective solutions, liquid biopsy's potential to
replace or reduce the need for invasive procedures is propelling its adoption.
Early detection and personalized medicine are becoming key priorities for
European healthcare systems, and liquid biopsy plays a pivotal role in
advancing both.
Technological
innovations continue to drive the Europe Liquid Biopsy Market, with the
integration of next-generation sequencing (NGS) and liquid biopsy-based
companion diagnostics offering increased accuracy and broader applications.
Innovations in biomarker discovery, particularly those related to exosomal DNA
and ctDNA, are enhancing the precision of liquid biopsy tests. These
advancements allow for early detection of cancer at stages when it is most
treatable. Moreover, the growing awareness of the potential of liquid biopsy in
not just cancer detection but also in monitoring minimal residual disease and
predicting relapse, is contributing to its widespread acceptance. The evolution
of automated liquid biopsy platforms is also streamlining workflows in both
research and clinical laboratories, improving efficiency and scalability.
Despite
these challenges, several growth opportunities exist for the Europe Liquid
Biopsy Market. The expanding use of liquid biopsy in early-stage cancer
detection and post-treatment monitoring offers significant market potential,
especially as technologies continue to improve. Strategic partnerships between
biotech firms and pharmaceutical companies for the development of liquid
biopsy-based companion diagnostics are likely to provide new avenues for
growth. The increased focus on personalized medicine and the growing trend of
targeted therapies are creating demand for diagnostic tools that can offer
real-time insights into tumor evolution, further boosting the market. The
growing trend of at-home diagnostic testing and telemedicine integration
presents an exciting opportunity for liquid biopsy, as it could lead to more
widespread patient engagement and improved healthcare accessibility.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Europe Liquid Biopsy Market”
The Europe Liquid
Biopsy Market is segmented into offering, technology, application, end user, country
distribution, and company.
Based on the Technology,
Next Generation Sequencing (NGS) emerged as the fastest growing segment in the Europe
Liquid Biopsy Market during the forecast period. This is due to its ability to
offer highly accurate, high-throughput, and comprehensive genetic analysis. NGS
technology enables the sequencing of large amounts of DNA in a short period,
providing valuable insights into tumor DNA, circulating tumor cells (CTCs), and
other biomarkers present in the bloodstream. This capability is crucial for
detecting genetic mutations, identifying novel biomarkers, and monitoring
disease progression, making it an ideal tool for liquid biopsy applications. The
increasing demand for non-invasive cancer diagnostics is a key driver behind
the growth of NGS in liquid biopsy. NGS allows for early cancer detection,
monitoring treatment efficacy, and detecting minimal residual disease (MRD),
all of which are critical for personalized cancer treatment plans. As cancer
treatment moves towards more targeted and precision-based therapies, the need
for highly accurate and sensitive diagnostic tools like NGS has significantly
increased.
Based
on the Country, United Kingdom emerged as the fastest growing country in the Europe
Liquid Biopsy Market during
the forecast period. This is due to several key factors. One of the primary
drivers is the country's strong focus on advancing healthcare technologies,
particularly in the field of oncology. The UK has made significant strides in
integrating cutting-edge diagnostic tools like liquid biopsy into routine
clinical practice. The government’s support for precision medicine and early
cancer detection initiatives, coupled with strong funding for cancer research,
has created a favorable environment for the growth of liquid biopsy
technologies. Additionally, the UK’s healthcare infrastructure is well-equipped
to support the widespread use of liquid biopsy, with National Health Service
(NHS) incorporating such advanced diagnostics into its framework. The adoption
of liquid biopsy is also driven by a rising demand for non-invasive,
cost-effective diagnostic methods, especially given the increasing cancer
burden in the UK.
Major
companies operating in Europe Liquid Biopsy Market are:
- QIAGEN
N.V.
- Epigenomics
AG
- Inivata
Ltd.
- Sysmex
Inostics GmbH
- Stilla
Technologies
- Novigenix
SA
- Eurofins
Genomics Europe
- Chronix
Biomedical GmbH
- Genseq
Ltd.
- Blueberry
Therapeutics Ltd.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Europe Liquid Biopsy Market is
expanding due to the growing utilization of liquid biopsy techniques in
non-invasive prenatal testing (NIPT), which enables the detection of fetal
genetic conditions such as trisomy 21, 18, and 13 through a simple maternal
blood sample. This approach significantly reduces the risks associated with
traditional invasive methods like chorionic villus sampling and amniocentesis.
The increasing preference for safer, earlier, and more accurate prenatal
screening solutions is driving demand across hospitals and diagnostic centers.
As awareness about reproductive genetic testing rises and technology becomes
more accessible, the adoption of liquid biopsy in prenatal care is expected to
grow steadily.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Europe Liquid Biopsy
Market By Offering (Testing Services, Kits, Platform, Other Consumables), By
Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS),
Others), By Application (Oncological, Non-Oncological), By End User (Clinical
Laboratories, Academic & Research Institutes, Pharmaceutical &
Biotechnology Companies), By Country, Competition, Forecast and Opportunities,
2020-2030F”, has evaluated the future growth potential of Europe
Liquid Biopsy Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Europe Liquid Biopsy Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com